Clinical Research Directory
Browse clinical research sites, groups, and studies.
Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Sponsor: Pei-Rong Ding
Summary
Given the growing focus on preserving organ function and the utilization of neoadjuvant therapy, it is important to investigate and enhance the application of comprehensive neoadjuvant therapy in low rectal cancer. This approach aims to minimize or circumvent the organ dysfunction and subsequent decline in quality of life associated with radical surgery, with improving disease-free survival (DFS), while . Consequently, we propose to initiate a multicenter clinical trial to examine the medium- and long-term effectiveness of complete neoadjuvant therapy (comprising either short-course radiotherapy or long-course chemoradiation, followed by consolidation chemotherapy with mFOLFOXIRI) in increasing organ preservation rates in patients with low rectal cancer.
Official title: A Multicenter, Open, Randomized, Phase II Trial:Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2022-12-12
Completion Date
2025-12
Last Updated
2025-03-19
Healthy Volunteers
Yes
Conditions
Interventions
Short-course radiotherapy
The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
Irinotecan
150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Oxaliplatin
85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Calcium Formate
400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Fluorouracil
2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
Long-course chemoradiation
The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
Capecitabine
825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
Locations (1)
651 Dongfeng Road East
Guangzhou, Guangdong, China